ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MBRX Moleculin Biotech Inc

0.5398
0.0248 (4.82%)
Feb 23 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 143,189
Bid Price 0.502
Ask Price 0.5398
News -
Day High 0.54

Low
0.3377

52 Week Range

High
1.65

Day Low 0.491
Company Name Stock Ticker Symbol Market Type
Moleculin Biotech Inc MBRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0248 4.82% 0.5398 17:38:56
Open Price Low Price High Price Close Price Prev Close
0.512 0.491 0.54 0.5398 0.515
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
253 143,189 $ 0.5248606 $ 75,154 - 0.3377 - 1.65
Last Trade Time Type Quantity Stock Price Currency
17:00:24 17 $ 0.5398 USD

Moleculin Biotech Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
18.04M 33.41M - 0 -29.03M -0.87 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Moleculin Biotech News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MBRX Message Board. Create One! See More Posts on MBRX Message Board See More Message Board Posts

Historical MBRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.50530.540.47770.50224768,6030.03456.83%
1 Month0.490.56120.460.506408777,4980.049810.16%
3 Months0.58761.050.4470.6409582169,445-0.0478-8.13%
6 Months0.561.050.33770.5795197157,454-0.0202-3.61%
1 Year1.261.650.33770.6879202183,064-0.7202-57.16%
3 Years4.6654.770.33772.65260,068-4.13-88.43%
5 Years1.398.780.3231.831,115,361-0.8502-61.17%

Moleculin Biotech Description

Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.

Your Recent History

Delayed Upgrade Clock